PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
ARIAD Pharma (ARIA), PDL BioPharma (PDLI) Complete Iclusig-Related Royalty Transaction
July 29, 2015 7:39 AM EDTARIAD Pharma (Nasdaq: ARIA) announced that it will receive $100 million in cash $50 million upon deal execution late yesterday and an additional $50 million in one year through a synthetic-royalty financing from PDL BioPharma, Inc. (Nasdaq: PDLI) in exchange for paying PDL a mid-single-digit royalty on future sales of Iclusig (ponatinib) until PDL receives a fixed internal rate of return (IRR). ARIAD also has an option, in its discretion, to receive up to an additional $100 million at any time between 6 and 12 months from the date of the agreement,... More
ARIAD Pharma (ARIA) to Receive Up to $200M Through Synthetic-Royalty Financing with PDL BioPharma (PDLI)
July 29, 2015 7:39 AM EDTARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will receive $100 million in cash $50 million upon deal execution late yesterday and an additional $50 million in one year through a synthetic-royalty financing from PDL BioPharma, Inc. (NASDAQ: PDLI) in exchange for paying PDL a mid-single-digit royalty on future sales of Iclusig® (ponatinib) until PDL receives a fixed internal rate of return (IRR). ARIAD also has an option, in its discretion, to receive... More
